FDA, GSK and Meningococcal Groups

FDA approves more broadly protective meningococcal vaccine
The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive meningococcal disease (IMD), according to a press release from GlaxoSmithKline (GSK).
FDA Approves GSK's 5-in-1 Meningococcal Vaccine For Adolescents Ahead Of CDC Advisory Committee Vote Meeting Next Week
GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage recommendations on Feb. 26.
GSK’s 5-in-1 meningococcal shot wins FDA approval
Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through 25 years old.
Pentavalent Meningococcal Vaccine Penmenvy Gets FDA Approval
Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).
FDA approves GSK’s pentavalent meningococcal vaccine
The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against five meningococcal serogroups, the company announced.The vaccine, branded as Penmenvy,
GSK’s Penmenvy meningococcal vaccine gains FDA approval
The studies confirmed that the vaccine has a safety profile consistent with the licensed meningococcal vaccines of GSK. The integration of the MenABCWY vaccine into healthcare pra
GSK reports FDA approves Penmenvy 5-in-1 meningococcal vaccine
GSK (GSK) plc announced that the Food and Drug Administration has approved Penmenvy for use in individuals aged 10 through 25 years. The
With new FDA approval, GSK joins Pfizer in the 5-in-1 meningococcal vaccine ring
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to play catch-up after nabbing its own FDA approval.  | The company's Penmenvy combines components of its established MenB and MenACWY vaccines Bexsero and Menveo,
US FDA approves GSK's combo meningococcal vaccine
The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal infection for use in people aged 10 through 25 years, the company said on Saturday.
STAT9h
Pharmalittle: We’re reading about the impact of HHS firings, a GSK vaccine approval, and more
Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...
PharmiWeb1d
Meningococcal Vaccine Market Projected to Reach USD 9014 Million by 2034 at a 8.6% of CAGR
Meningococcal Vaccine MarketThe global meningococcal vaccine market is experiencing significant growth, driven by rising ...
Nova Scotia Health confirms case of invasive meningococcal disease at high school
Public Health said it investigated a case in a student last week at Cole Harbour High School. Close contacts were notified ...